StockData
MDxHealth SA logo

MDxHealth SA (MDXH) company profile

MDXHNasdaqServices-Medical Laboratories
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 3, 2026Score 5/30
$0.14−0.01 (-5.97%)

Close on Nov 18, 2026Market cap $719.62KP/E –Yield –

About MDxHealth

Services-Medical Laboratories, SIC 8071

MDxHealth SA is a commercial-stage molecular diagnostics company that develops and provides clinical diagnostic testing solutions, specializing in prostate cancer diagnostics and urological clinical conditions. The company's core product offerings include Confirm mdx, Exo mdx, GPS mdx, Resolve mdx, and Monitor mdx. These diagnostic tests are primarily utilized by healthcare providers, including medical practices, institutions, and urologists who make diagnostic recommendations, while payments and reimbursements for these services are processed through commercial health insurance companies, patients, and governmental healthcare payor programs such as Medicare and Medicaid.

The company operates clinical testing and research facilities, including a CLIA-certified clinical laboratory acquired through its Exosome Diagnostics business, supported by information technology and specialized laboratory equipment. MDxHealth SA maintains corporate headquarters and principal executive offices in Herstal, Belgium, alongside corporate and executive offices in Irvine, California, and an additional operating corporate entity based in the Netherlands.

Summary of the business section of MDxHealth's latest annual report, written by StockData.

Company profile

Company

Legal name
MDxHealth SA
Founded
2003
Headquarters
Herstal, C9
Address
Cap Business Center, Rue D'Abhooz, 31, B-4040 00000
Phone
(949) 271-9221
Employees
364, Dec 31, 2025
Industry
Services-Medical Laboratories
Incorporated in
C9
Auditor
BDO Reviseurs dEntreprises SRL, Zaventem, Belgium

Stock & identifiers

Ticker
MDXH
Exchange
Nasdaq
IPO date
Nov 5, 2021
Shares outstanding
51M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Emerging growth company
Stock splits
1-for-10 reverse, Apr 30, 2024
SEC CIK
1872529
CUSIP
B5950S113
FIGI
BBG000VBX3M3
Share class FIGI
BBG001SF8932
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Michael McGarrityChief Executive Officer, Director95,000
Joseph SolleeSee Remarks–
John BellanoChief Commercial Officer–
Brendan OConnellVP, Finance and Accounting–
Ron KalfusChief Financial Officer–
Eric BednarskiDirector6,903,100
MVM Partners, LLCDirector4,700,457
Koen HoffmanDirector–
Don M. HardisonDirector–
Sanford Jay SiegelDirector–
Hilde WindelsDirector–
Michael HolderDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 5, 2021
Offer price
$12.00
Securities offered
3,750,000
Gross proceeds
$45.00M
Exchange
Nasdaq
First trading day
Nov 4, 2021
First-day close
$12.000.0%
Lock-up ends (est.)
May 3, 2022

“The initial public offering price is $12.00 per ADS.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 364 employees,”

Corporate history

Events identified from SEC filings

See a number that looks wrong?